HTA in the news

Insurers, Employers Face Pressure to Match Trump Deals on Drugs

Bloomberg Law

The Trump administration’s deal to lower the cash price of blockbuster weight-loss drugs is heightening pressure on employers and insurers to negotiate better costs with the drugmakers, say lawyers, academics, and executives.

Read more

Obesity Drugs May Drop to as Little as $150 a Month

The New York Times

President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay their own money.

Read more

TrumpRx Pfizer Drug Pricing

Pharmacy Practice News

The Trump administration’s newly unveiled “TrumpRx” initiative—a partnership with Pfizer framed as the first step toward applying most-favored-nation (MFN) drug pricing in the United States—is being touted as a game changer in making prescription drugs more affordable.

Read more

TrumpRx Pfizer Drug Pricing

Specialty Pharmacy Continuum

The Trump administration’s newly unveiled “TrumpRx” initiative—a partnership with Pfizer framed as the first step toward applying most-favored-nation (MFN) drug pricing in the United States—is being touted as a game changer in making prescription drugs more affordable.

Read more

End of Premium Tax Credits Could Hit Hospitals Financially

Medscape

Enrollment in the Affordable Care Act (ACA) Marketplace has doubled since the introduction of enhanced premium tax credits in 2021, providing health insurance coverage for more than 24 million Americans.

Read more

The policies top of mind for healthcare stakeholders right now.

Fierce Healthcare’s Podnosis Podcast

Amid a breakneck pace of regulatory changes under the Trump administration, healthcare stakeholders are scrambling to keep up.

Listen now

Employers find success in healthcare savings through TPA shift and payment integrity

Healthcare Financial Management Association

Tiering and steering designs in their employee health plans also have driven 11% to 12% reductions in healthcare costs.

Read more

TrumpRx Effects on Medicaid Rebates, Cost-Shifting, and Value-Based Drug Pricing: Robert Andrews

American Journal of Managed Care

Robert Andrews, CEO of the Health Transformation Alliance, addresses Medicaid rebates, cost-shifting concerns, and value-based pricing trends.

Read more

Press contact details

Berkeley Communications

HTAUS@berkeleypr.com